This news release is based on interesting research. But the release leaves too many holes that might prevent journalists and the public from grasping what the findings may mean — or not.
This news release describes a study testing three drugs for diabetic macular edema with price tags ranging from about $700 to $17,700 for a round of treatment.
FoxNews.com labels this piece as “news” – not as an opinion piece by one physician. To use the columnist’s own words in a different context, “I find this outrageous.”
Subgroup analysis is an important approach to experimental trials that journalists – and the general public need to understand. This news release didn’t even raise the issue.
Tips for Understanding Studies